279 related articles for article (PubMed ID: 24172061)
1. Different effects of epigenetic modifiers on the cytotoxicity induced by 5-fluorouracil, irinotecan or oxaliplatin in colon cancer cells.
Ikehata M; Ogawa M; Yamada Y; Tanaka S; Ueda K; Iwakawa S
Biol Pharm Bull; 2014; 37(1):67-73. PubMed ID: 24172061
[TBL] [Abstract][Full Text] [Related]
2. Different Schedule-Dependent Effects of Epigenetic Modifiers on Cytotoxicity by Anticancer Drugs in Colorectal Cancer Cells.
Hosokawa M; Tanaka S; Ueda K; Iwakawa S
Biol Pharm Bull; 2017 Dec; 40(12):2199-2204. PubMed ID: 28954936
[TBL] [Abstract][Full Text] [Related]
3. MSH3 mismatch repair protein regulates sensitivity to cytotoxic drugs and a histone deacetylase inhibitor in human colon carcinoma cells.
Park JM; Huang S; Tougeron D; Sinicrope FA
PLoS One; 2013; 8(5):e65369. PubMed ID: 23724141
[TBL] [Abstract][Full Text] [Related]
4. Effects of the HDAC inhibitor CG2 in combination with irinotecan, 5-fluorouracil, or oxaliplatin on HCT116 colon cancer cells and xenografts.
Na YS; Kim SM; Jung KA; Yang SJ; Hong YS; Ryu MH; Ro S; Cho DH; Kim JC; Jin DH; Lee JS; Kim TW
Oncol Rep; 2010 Dec; 24(6):1509-14. PubMed ID: 21042746
[TBL] [Abstract][Full Text] [Related]
5. Different involvement of DNA methylation and histone deacetylation in the expression of solute-carrier transporters in 4 colon cancer cell lines.
Ikehata M; Ueda K; Iwakawa S
Biol Pharm Bull; 2012; 35(3):301-7. PubMed ID: 22382314
[TBL] [Abstract][Full Text] [Related]
6. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
[TBL] [Abstract][Full Text] [Related]
7. Synergistic Effect of Epigenetic Inhibitors Decitabine and Suberoylanilide Hydroxamic Acid on Colorectal Cancer In vitro.
Abou Najem S; Khawaja G; Hodroj MH; Rizk S
Curr Mol Pharmacol; 2019; 12(4):281-300. PubMed ID: 30868973
[TBL] [Abstract][Full Text] [Related]
8. Identification of a potent epigenetic biomarker for resistance to camptothecin and poor outcome to irinotecan-based chemotherapy in colon cancer.
Miyaki Y; Suzuki K; Koizumi K; Kato T; Saito M; Kamiyama H; Maeda T; Shibata K; Shiya N; Konishi F
Int J Oncol; 2012 Jan; 40(1):217-26. PubMed ID: 21901246
[TBL] [Abstract][Full Text] [Related]
9. Colon cancer: new drug options improve on 5-FU.
McCann J
J Natl Cancer Inst; 1998 Jul; 90(13):963-5. PubMed ID: 9665142
[No Abstract] [Full Text] [Related]
10. The sirtuin inhibitor tenovin-6 upregulates death receptor 5 and enhances cytotoxic effects of 5-fluorouracil and oxaliplatin in colon cancer cells.
Ueno T; Endo S; Saito R; Hirose M; Hirai S; Suzuki H; Yamato K; Hyodo I
Oncol Res; 2013; 21(3):155-64. PubMed ID: 24512730
[TBL] [Abstract][Full Text] [Related]
11. Decitabine exerted synergistic effects with oxaliplatin in colorectal cancer cells with intrinsic resistance to decitabine.
Hosokawa M; Tanaka S; Ueda K; Iwakawa S; Ogawara KI
Biochem Biophys Res Commun; 2019 Jan; 509(1):249-254. PubMed ID: 30581001
[TBL] [Abstract][Full Text] [Related]
12. Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cells.
Raymond E; Louvet C; Tournigand C; Coudray AM; Faivre S; De Gramont A; Gespach C
Int J Oncol; 2002 Aug; 21(2):361-7. PubMed ID: 12118332
[TBL] [Abstract][Full Text] [Related]
13. Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer.
Alzoubi S; Brody L; Rahman S; Mahul-Mellier AL; Mercado N; Ito K; El-Bahrawy M; Silver A; Boobis A; Bell JD; Hajji N
Oncotarget; 2016 Jul; 7(28):44505-44521. PubMed ID: 27283986
[TBL] [Abstract][Full Text] [Related]
14. DNA methyltransferase inhibitors improve the effect of chemotherapeutic agents in SW48 and HT-29 colorectal cancer cells.
Flis S; Gnyszka A; Flis K
PLoS One; 2014; 9(3):e92305. PubMed ID: 24676085
[TBL] [Abstract][Full Text] [Related]
15. Irinotecan overcomes the resistance to 5-fluorouracil in human colon cancer xenografts by down-regulation of intratumoral thymidylate synthase.
Fukushima M; Sakamoto K; Ohshimo H; Nakagawa F; Taguchi T
Oncol Rep; 2010 Oct; 24(4):835-42. PubMed ID: 20811661
[TBL] [Abstract][Full Text] [Related]
16. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
[TBL] [Abstract][Full Text] [Related]
17. Acquired resistance to decitabine and cross-resistance to gemcitabine during the long-term treatment of human HCT116 colorectal cancer cells with decitabine.
Hosokawa M; Saito M; Nakano A; Iwashita S; Ishizaka A; Ueda K; Iwakawa S
Oncol Lett; 2015 Aug; 10(2):761-767. PubMed ID: 26622566
[TBL] [Abstract][Full Text] [Related]
18. Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer.
Fioravanti A; Canu B; Alì G; Orlandi P; Allegrini G; Di Desidero T; Emmenegger U; Fontanini G; Danesi R; Del Tacca M; Falcone A; Bocci G
Eur J Pharmacol; 2009 Oct; 619(1-3):8-14. PubMed ID: 19695243
[TBL] [Abstract][Full Text] [Related]
19. Effects of Decitabine on Invasion and Exosomal Expression of miR-200c and miR-141 in Oxaliplatin-Resistant Colorectal Cancer Cells.
Tanaka S; Hosokawa M; Ueda K; Iwakawa S
Biol Pharm Bull; 2015; 38(9):1272-9. PubMed ID: 26179333
[TBL] [Abstract][Full Text] [Related]
20. Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer.
Grivicich I; Mans DR; Peters GJ; Schwartsmann G
Braz J Med Biol Res; 2001 Sep; 34(9):1087-103. PubMed ID: 11514832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
